Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AB122 + AB154 with platinum-based chemotherapy in first-line metastatic non-small cell lung cancer
jRCT2051230009Phase 1Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of zimberelimab and domvanalimab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Dose-limiting toxicity occurrence rate during Cycle 1. Started May 2023; status: active, not recruiting.
02
Drugs
zimberelimabdomvanalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051230009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230009.